Strata Critical Medical (SRTA) Cash from Financing Activities (2019 - 2026)

Strata Critical Medical has disclosed Cash from Financing Activities across 7 years of filings, most recently posting -$859000.0 for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 79.77% year-over-year to -$859000.0; the TTM figure through Mar 2026 stood at -$5.5 million (up 45.07% YoY), while the FY2025 annual figure was -$8.9 million, down 54.75% from the prior year.
• Cash from Financing Activities improved to -$859000.0 in Q1 2026, from -$1.7 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for SRTA reached as high as $54000.0 in Q1 2024 and fell as low as -$4.2 million in Q1 2025.
• The 5-year median for Cash from Financing Activities is -$859000.0 (2026), against an average of -$1.1 million.
• The widest YoY moves for Cash from Financing Activities: up 300.0% in 2024, down 16743.48% in 2024.
• A 5-year view of Cash from Financing Activities shows it stood at -$932000.0 in 2022, then jumped by 97.53% to -$23000.0 in 2023, then slumped by 16743.48% to -$3.9 million in 2024, then surged by 55.03% to -$1.7 million in 2025, then surged by 50.69% to -$859000.0 in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered -$859000.0, -$1.7 million, and -$1.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.